Interleukin-10: Potential benefits and possible risks in clinical infectious diseases

被引:86
作者
Opal, SM
Wherry, JC
Grint, P
机构
[1] Brown Univ, Sch Med, Div Infect Dis, Providence, RI 02912 USA
[2] Schering Plough Res Inst, Clin Immunol Infect Dis Div, Kenilworth, NJ USA
关键词
D O I
10.1086/515032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that inhibits the synthesis of the major proinflammatory cytokines and chemokines. IL-10 is the principal TH2-type cytokine that upregulates humoral immune responses and attenuates cell-mediated immune reactions. This cytokine has a number of immunomodulatory properties that might be clinically useful in a variety of inflammatory and infectious disease states. Clinical trials with human recombinant IL-10 are already in progress. Carefully selected patients with inflammatory conditions may benefit from IL-10 therapy if concomitant infectious diseases are recognized and treated appropriately.
引用
收藏
页码:1497 / 1507
页数:11
相关论文
共 137 条
[1]   Interferon-alpha stimulates production of interleukin-10 in activated CD4(+) T cells and monocytes [J].
Aman, MJ ;
Tretter, T ;
Eisenbeis, I ;
Bug, G ;
Decker, T ;
Aulitzky, WE ;
Tilg, H ;
Huber, C ;
Peschel, C .
BLOOD, 1996, 87 (11) :4731-4736
[2]  
ARARI T, 1995, IMMUNOLOGY, V85, P381
[3]   Evidence of a T helper type 2 activation in human schistosomiasis [J].
Araujo, MI ;
deJesus, AR ;
Bacellar, O ;
Sabin, E ;
Pearce, E ;
Carvalho, EM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (06) :1399-1403
[4]   THE INTERFERONS - MECHANISMS OF ACTION AND CLINICAL-APPLICATIONS [J].
BARON, S ;
TYRING, SK ;
FLEISCHMANN, WR ;
COPPENHAVER, DH ;
NIESEL, DW ;
KLIMPEL, GR ;
STANTON, GJ ;
HUGHES, TK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (10) :1375-1383
[5]   INTERLEUKIN-10 PROTECTS MICE AGAINST STAPHYLOCOCCAL-ENTEROTOXIN B-INDUCED LETHAL SHOCK [J].
BEAN, AGD ;
FREIBERG, RA ;
ANDRADE, S ;
MENON, S ;
ZLOTNIK, A .
INFECTION AND IMMUNITY, 1993, 61 (11) :4937-4939
[6]   Cytokine levels after open and laparoscopic cholecystectomy [J].
Bellon, JM ;
Manzano, L ;
Bernardos, L ;
GaHonduvilla, N ;
Larrad, A ;
Bujan, J ;
AlvarezMon, M .
EUROPEAN SURGICAL RESEARCH, 1997, 29 (01) :27-34
[7]   INTERLEUKIN-10 BUT NOT INTERLEUKIN-4 IS A NATURAL SUPPRESSANT OF CUTANEOUS INFLAMMATORY RESPONSES [J].
BERG, DJ ;
LEACH, MW ;
KUHN, R ;
RAJEWSKY, K ;
MULLER, W ;
DAVIDSON, NJ ;
RENNICK, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :99-108
[8]   INTERLEUKIN-10 IS A CENTRAL REGULATOR OF THE RESPONSE TO LPS IN MURINE MODELS OF ENDOTOXIC-SHOCK AND THE SHWARTZMAN REACTION BUT NOT ENDOTOXIN TOLERANCE [J].
BERG, DJ ;
KUHN, R ;
RAJEWSKY, K ;
MULLER, W ;
MENON, S ;
DAVIDSON, N ;
GRUNIG, G ;
RENNICK, D .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (05) :2339-2347
[9]   INFECTION WITH MYCOBACTERIUM-AVIUM INDUCES PRODUCTION OF INTERLEUKIN-10 (IL-10), AND ADMINISTRATION OF ANTI-IL-10 ANTIBODY IS ASSOCIATED WITH ENHANCED RESISTANCE TO INFECTION IN MICE [J].
BERMUDEZ, LE ;
CHAMPSI, J .
INFECTION AND IMMUNITY, 1993, 61 (07) :3093-3097
[10]   MACROPHAGE DEACTIVATION BY INTERLEUKIN-10 [J].
BOGDAN, C ;
VODOVOTZ, Y ;
NATHAN, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1549-1555